Skip to main content
NASDAQ:CMMB

Chemomab Therapeutics Stock Forecast, Price & News

$17.16
-0.82 (-4.56 %)
(As of 05/12/2021 12:00 AM ET)
Add
Compare
Today's Range
$16.52
$18.25
50-Day Range
$17.98
$55.00
52-Week Range
$12.32
$168.80
Volume128,711 shs
Average Volume217,468 shs
Market Capitalization$40.10 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive CMMB News and Ratings via Email

Sign-up to receive the latest news and ratings for Chemomab Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


About Chemomab Therapeutics

Chemomab Therapeutics Ltd. engages in the research and development of biological drugs for the treatment of inflammatory and fibrotic diseases. The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 16, 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CMMB
CUSIPN/A
CIKN/A
Phone972 77 331 0156
EmployeesN/A
Year FoundedN/A

Sales & Book Value

Annual SalesN/A

Profitability

Debt

Price-To-Earnings

Miscellaneous

Market Cap$40.10 million
Next Earnings Date5/13/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.70 out of 5 stars

Medical Sector

266th out of 2,045 stocks

Biotechnology Industry

17th out of 158 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Chemomab Therapeutics (NASDAQ:CMMB) Frequently Asked Questions

Is Chemomab Therapeutics a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Chemomab Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Chemomab Therapeutics stock.
View analyst ratings for Chemomab Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Chemomab Therapeutics?

Wall Street analysts have given Chemomab Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Chemomab Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Chemomab Therapeutics' next earnings date?

Chemomab Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, May 13th 2021.
View our earnings forecast for Chemomab Therapeutics
.

What price target have analysts set for CMMB?

1 equities research analysts have issued 1-year target prices for Chemomab Therapeutics' shares. Their forecasts range from $42.00 to $42.00. On average, they anticipate Chemomab Therapeutics' share price to reach $42.00 in the next twelve months. This suggests a possible upside of 144.8% from the stock's current price.
View analysts' price targets for Chemomab Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Chemomab Therapeutics' key executives?

Chemomab Therapeutics' management team includes the following people:
  • Dr. Adi Mor George Ph.D., Co-Founder, CEO, Chief Scientific Officer & Director (Age 39)
  • Ms. Sigal Fattal, Interim Chief Financial Officer (Age 50)
  • Dr. Arnon Aharon, Chief Medical Officer (Age 52)

Who are some of Chemomab Therapeutics' key competitors?

What is Chemomab Therapeutics' stock symbol?

Chemomab Therapeutics trades on the NASDAQ under the ticker symbol "CMMB."

Who are Chemomab Therapeutics' major shareholders?

Chemomab Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Meitav Dash Investments Ltd. (0.36%).

Which institutional investors are buying Chemomab Therapeutics stock?

CMMB stock was purchased by a variety of institutional investors in the last quarter, including Meitav Dash Investments Ltd..

How do I buy shares of Chemomab Therapeutics?

Shares of CMMB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Chemomab Therapeutics' stock price today?

One share of CMMB stock can currently be purchased for approximately $17.16.

How much money does Chemomab Therapeutics make?

Chemomab Therapeutics has a market capitalization of $40.10 million.

What is Chemomab Therapeutics' official website?

The official website for Chemomab Therapeutics is www.chemomab.com.

How can I contact Chemomab Therapeutics?

The company can be reached via phone at 972 77 331 0156.


This page was last updated on 5/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.